Do I Need a Myasthenia Gravis Infusion?
An infusion for myasthenia gravis may be recommended if symptoms are moderate to severe, or when other treatments aren’t providing enough relief.
Myasthenia gravis is a chronic autoimmune disorder that disrupts the communication between nerves and muscles, resulting in muscle weakness. Because symptoms tend to worsen with activity and improve with rest, even routine tasks like walking or speaking can become difficult for some. While some people experience only mild issues, others may find the disease interferes with essential tasks like speaking, walking, or breathing.
There are several ways to manage the condition today, including oral medications and surgical options. In some cases, intravenous therapies may be recommended when first-line myasthenia gravis treatments fall short.
What Infusions Are Given for Myasthenia Gravis?
There are multiple FDA-approved infusion therapies for myasthenia gravis, each targeting different parts of the immune system to reduce harmful antibodies.
Common options include:
- Eculizumab (Soliris®) and Ravulizumab (Ultomiris®): These complement inhibitors reduce immune system activity and are administered through IV infusion. Ravulizumab is longer-acting and requires less frequent dosing.
- Efgartigimod (Vyvgart®): A targeted therapy that lowers antibody levels in the bloodstream. It’s delivered in cycles—one infusion per week for four weeks.
- Rozanolixizumab-noli (Rystiggo®): This subcutaneous infusion is approved for patients with both AChR and MuSK antibody-positive myasthenia gravis.
- Rituximab (Rituxan®): Though not FDA-approved specifically for this condition, rituximab is often used off-label in patients with MuSK-positive myasthenia gravis and has shown strong long-term remission potential.
Based on your treatment history and antibody profile, your provider will determine the most effective option.